Dr. Jonathan Drachman is Chief Executive Officer and Co-Founder of StradBio. He brings more than two decades of drug development experience, including 14 years at Seattle Genetics, where he served in multiple leadership roles, including Chief Medical Officer and Executive Vice President of Research and Development.

He subsequently co-founded Neoleukin Therapeutics and served as its Chief Executive Officer, advancing innovative protein-based therapeutics. Earlier in his career, Dr. Drachman led an academic research laboratory at the University of Washington. He has also served on the boards of multiple public and private biotechnology companies.

Dr. Drachman received his MD from Harvard Medical School and completed his training in internal medicine and medical oncology at the University of Washington. He currently serves as a member of the MBrace Therapeutics Scientific Advisory Board.